A month after shelving its previous lead drug candidate, izokibep, Acelyrin said on 6 January that it is moving lonigutamab into Phase III in thyroid eye disease with a revised dosing regimen from Phase I/II and a goal of replacing Amgen’s Tepezza (teprotumumab) as the standard of care. However, some analysts viewed the updated results from Acelyrin’s Phase I/II study as strengthening the case of Viridian’s veligrotug to become the gold-standard therapy in TED.
Acelyrin To Take Tepezza Competitor Into Phase III In TED
Investors Seem Unconvinced
With new Phase I/II data for its anti-IGF-1 agent lonigutamab, Acelyrin will move into Phase III in thyroid eye disease. But how competitive it will be versus Tepezza or Viridian’s Phase III candidate is uncertain.
